Debt-free Orchid Pharma charts out growth plan

Orchid Pharma, backed by Dhanuka Group, focuses on cephalosporin antibiotics. Expansion plans include a new facility, Enmetazobactam launch, and mergers for sustainable growth and reduced import reliance.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news